Viridian Therapeutics Inc VRDN Stock Analysis
- Nasdaq
- Stock
- Market open · no trades yet today
$28.55 down $0.51, 1.74% at close Nov 5
Last close · Previous close $29.06
- Market cap
- $3.23BAt the Nov 5 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$3.86Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$28.55down $0.50, 1.74%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$29.06Nov 4
- Volume3.44MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.71MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $13.18 to $34.29; now $28.55
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VRDN beat the S&P 500 in 4 of 7 periods.
| Period | VRDN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VRDN: up 50.3% S&P 500: down 5.4% | VRDN beat the S&P 500 by 55.7 percentage points Beat |
| 3M | VRDN: up 35.5% S&P 500: down 4.5% | VRDN beat the S&P 500 by 40.0 percentage points Beat |
| YTD | VRDN: down 8.3% S&P 500: up 8.3% | VRDN trailed the S&P 500 by 16.6 percentage points Trailed |
| 1Y | VRDN: up 16.9% S&P 500: up 9.3% | VRDN beat the S&P 500 by 7.6 percentage points Beat |
| Long term | ||
| 3Y | VRDN: up 88.0% S&P 500: up 74.8% +23.4% vs +20.5% a year | VRDN beat the S&P 500 by 13.2 percentage points Beat |
| 5Y | VRDN: up 50.3% S&P 500: up 67.3% +8.5% vs +10.8% a year | VRDN trailed the S&P 500 by 17.0 percentage points Trailed |
| 10Y | VRDN: down 44.8% S&P 500: up 311.8% −5.8% vs +15.2% a year | VRDN trailed the S&P 500 by 356.6 percentage points Trailed |
$10,000 invested in VRDN 10 years ago (Nov 4, 2016) would be worth about $5,517 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,184.
VRDN beat the S&P 500 in 4 of 7 periods.
| Period | VRDN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VRDN: up 50.3% S&P 500: down 5.4% | VRDN beat the S&P 500 by 55.7 percentage points Beat |
| 3M | VRDN: up 35.5% S&P 500: down 4.8% | VRDN beat the S&P 500 by 40.3 percentage points Beat |
| YTD | VRDN: down 8.3% S&P 500: up 7.5% | VRDN trailed the S&P 500 by 15.8 percentage points Trailed |
| 1Y | VRDN: up 16.9% S&P 500: up 8.2% | VRDN beat the S&P 500 by 8.7 percentage points Beat |
| Long term | ||
| 3Y | VRDN: up 88.0% S&P 500: up 68.6% +23.4% vs +19.0% a year | VRDN beat the S&P 500 by 19.4 percentage points Beat |
| 5Y | VRDN: up 50.3% S&P 500: up 56.4% +8.5% vs +9.4% a year | VRDN trailed the S&P 500 by 6.1 percentage points Trailed |
| 10Y | VRDN: down 44.8% S&P 500: up 251.5% −5.8% vs +13.4% a year | VRDN trailed the S&P 500 by 296.3 percentage points Trailed |
$10,000 invested in VRDN 10 years ago (Nov 4, 2016) would be worth about $5,517 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,147.
All-time high
$2,045.25
Closing high on . Now 98.6% below that record.
Split-adjusted daily closes since Jun 18, 2014.
Stock splits
2
Latest: 1-for-15 on . Share counts adjust after each split.
Both splits
- 1-for-15
- 1-for-15
Valuation
The Nov 5 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$3.86 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 122.9×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 5.6×Book value as of Sep 30, 2026
Price relative to accounting equity (book value) per share on the Sep 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −10.62%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $2.64BAt the Nov 5 close
What it would cost to buy the whole business: the market cap at the Nov 5 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own VRDN DCF in Excel. Value Viridian Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $26.31Mdown 62.8%
- Net income
- −$453.58M
- Diluted EPS
- −$3.86
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $72.00K | −$79.73M | −$0.81 |
| Q1 FY25 (Mar 31, 2025) | $72.00K | −$86.91M | −$0.87 |
| Q2 FY25 (Jun 30, 2025) | $75.00K | −$100.74M | −$1.00 |
| Q3 FY25 (Sep 30, 2025) | $70.57M | −$34.60M | −$0.34 |
| Q4 FY25 (Dec 31, 2025) | $132.00K | −$120.36M | −$1.10 |
| Q1 FY26 (Mar 31, 2026) | $141.00K | −$104.90M | −$0.90 |
| Q2 FY26 (Jun 30, 2026) | $284.00K | −$127.12M | −$1.05 |
| Q3 FY26 (Sep 30, 2026) | $25.75M | −$101.21M | −$0.81 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $2.96M | −$79.41M | −$6.66 |
| FY22 (Dec 31, 2022) | $1.77M | −$129.87M | −$2.71 |
| FY23 (Dec 31, 2023) | $314.00K | −$237.73M | −$3.91 |
| FY24 (Dec 31, 2024) | $302.00K | −$269.95M | −$3.07 |
| FY25 (Dec 31, 2025) | $70.85M | −$342.60M | −$3.32 |
Margins
- Gross 94.2%
- Operating −1,781.4%
- Net −1,724.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$343.44MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$341.51MLast 12 months
- Capital spending$1.94MLast 12 months
- −1,305.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $474.30MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $956.51MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$364.07MAs of Sep 30, 2026
- Net cash$592.44MAs of Sep 30, 2026
- 14.46As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.63As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −69.8%Last 12 months
Over the last 12 months, Viridian Therapeutics lost money: its net loss was 69.8% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −47.6%Last 12 months
Over the last 12 months, Viridian Therapeutics’s net loss was 47.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Viridian Therapeutics Inc
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug, including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED franchise, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VRDN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VRDN stock FAQ
What is VRDN stock’s price today?
Viridian Therapeutics (VRDN) traded at $28.55 at the close on , down $0.51 (1.74%) from the previous close of $29.06. Over the past 52 weeks it has traded between $13.18 and $34.29.
If you invested $1,000 in VRDN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in VRDN on would be worth about $552 at the close on , a total return of −44.8%. The same $1,000 would be worth $1,503 if invested five years ago and $1,169 if invested one year ago. Past performance doesn’t predict future returns.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market capitalization is about $3.2 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $28.55 (how market cap works). Viridian Therapeutics reported 113.29M shares outstanding at the end of its latest quarter ().
What is VRDN’s P/E ratio?
VRDN’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$3.86).
How much revenue does Viridian Therapeutics make?
Viridian Therapeutics reported $26.3 million of revenue over the four quarters to , down 62.8% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $25.8 million, down 63.5% from a year earlier.
Is Viridian Therapeutics profitable?
Not over the four quarters to . Viridian Therapeutics reported a net loss of $453.6 million across those four quarters on $26.3 million of revenue.
What are VRDN’s earnings per share?
VRDN’s diluted earnings per share were −$3.86 over the four quarters to , compared with −$3.02 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.81 per share, against −$0.34 a year earlier (how EPS works).
Does VRDN pay a dividend?
Viridian Therapeutics hasn’t paid a dividend in the last twelve months.
What is VRDN’s 52-week high and low?
Over the past 52 weeks VRDN has traded as low as $13.18 and as high as $34.29. At $28.55 at the close on , it is 16.7% below that high and 116.6% above the low.
What is VRDN’s all-time high?
VRDN’s highest closing price was $2,045.25 on , adjusted for stock splits. At $28.55 at the close on , it is 98.6% below that record.
Has VRDN stock ever split?
Yes, twice: 1-for-15 on ; 1-for-15 on .
How has VRDN stock performed?
Including dividends and measured to the close on , VRDN has returned −8.3% so far this year and +16.9% over the past year, and +50.3% over five years (+8.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is Viridian Therapeutics in?
Viridian Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does VRDN trade on?
Viridian Therapeutics trades on the Nasdaq under the ticker symbol VRDN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.